Tag #Sglt-2 Inhibitors

Showing 1 to 4 of 4 results

bbc.com

🌐 85% Global Worthiness

Aug 20, 04:16

NICE Recommends Personalized Treatment for Type 2 Diabetes in UK

NICE recommends personalized type 2 diabetes treatment in England, Wales, and Northern Ireland, prioritizing SGLT-2 inhibitors as first-line treatment for all 4.6 million diagnosed patients, potentially saving 22,000 lives and reducing NHS costs, but addressing unequal access is crucial.

NICE Recommends Personalized Treatment for Type 2 Diabetes in UK

NICE recommends personalized type 2 diabetes treatment in England, Wales, and Northern Ireland, prioritizing SGLT-2 inhibitors as first-line treatment for all 4.6 million diagnosed patients, potentially saving 22,000 lives and reducing NHS costs, but addressing unequal access is crucial.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate implications of NICE's recommendation to prioritize SGLT-2 inhibitors for all type 2 diabetes patients in England, Wales, and Northern Ireland?

NICE recommends a personalized approach to type 2 diabetes treatment in England, Wales, and Northern Ireland, prioritizing SGLT-2 inhibitors as first-line treatment for all patients. This could save 22,000 lives and reduce NHS costs. Access to these drugs is currently unequal across the UK, disproportionately affecting women, older people, and Black people.

kathimerini.gr

🌐 85% Global Worthiness

Jun 10, 10:11

SGLT-2 Inhibitors Added to Heart Failure Treatment Guidelines

New guidelines recommend SGLT-2 inhibitors for heart failure patients, improving outcomes and reducing hospitalizations; studies show reduced death and hospitalization risks compared to standard care; this is due to their diuretic effects and positive impact on kidney function, thus benefiting both ...

SGLT-2 Inhibitors Added to Heart Failure Treatment Guidelines

New guidelines recommend SGLT-2 inhibitors for heart failure patients, improving outcomes and reducing hospitalizations; studies show reduced death and hospitalization risks compared to standard care; this is due to their diuretic effects and positive impact on kidney function, thus benefiting both ...

Progress

28% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do SGLT-2 inhibitors impact heart failure patients, and what evidence supports their efficacy?

The addition of SGLT-2 inhibitors to heart failure treatment significantly alters the therapeutic landscape. Studies published in The New England Journal of Medicine (October 14, 2021) and The Lancet (September 19, 2020) demonstrate reduced risks of death and hospitalization in patients with both HFrEF and HFpEF who received SGLT-2 inhibitors, compared to those receiving standard care. This improvement is attributed to SGLT-2 inhibitors' diuretic effect, sodium level reduction, and weight loss benefits, alongside their positive impact on kidney function.

dailymail.co.uk

🌐 85% Global Worthiness

Aug 20, 04:16

NICE Recommends Overhaul of Type 2 Diabetes Treatment

NICE recommends earlier use of weight-loss drugs and SGLT-2 inhibitors for type 2 diabetes, shifting to personalized care to prevent complications and save lives; the change could save almost 22,000 lives with 90% patient uptake.

NICE Recommends Overhaul of Type 2 Diabetes Treatment

NICE recommends earlier use of weight-loss drugs and SGLT-2 inhibitors for type 2 diabetes, shifting to personalized care to prevent complications and save lives; the change could save almost 22,000 lives with 90% patient uptake.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does NICE's recommendation to personalize treatment address existing health inequalities in type 2 diabetes care?

NICE's updated guidelines address the under-prescription of SGLT-2 inhibitors, particularly among women, older adults, and Black patients, highlighting health inequalities. The shift to personalized treatment, incorporating factors like age, existing conditions, and response to metformin, aims to improve outcomes and reduce disparities. This holistic approach considers cardiovascular and kidney health alongside blood sugar control.

elmundo.es

🌐 85% Global Worthiness

Mar 29, 22:12

Dapagliflozin Improves Outcomes in Post-TAVI Aortic Stenosis Patients

A clinical trial involving 1,250 patients with severe aortic stenosis demonstrated that dapagliflozin, an SGLT-2 inhibitor, significantly reduced mortality and hospital readmissions for heart failure following transcatheter aortic valve implantation (TAVI), prompting calls for updated clinical guide...

Dapagliflozin Improves Outcomes in Post-TAVI Aortic Stenosis Patients

A clinical trial involving 1,250 patients with severe aortic stenosis demonstrated that dapagliflozin, an SGLT-2 inhibitor, significantly reduced mortality and hospital readmissions for heart failure following transcatheter aortic valve implantation (TAVI), prompting calls for updated clinical guide...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does this study address the limitations of previous research on SGLT-2 inhibitors and heart failure in elderly patients?

The DapaTAVI trial highlights the potential for dapagliflozin to improve the prognosis of patients with aortic stenosis after TAVI, a less invasive procedure for older patients. The study's success underscores the need to revise clinical guidelines to include SGLT-2 inhibitors as a standard post-TAVI treatment for high-risk patients. This is crucial given that up to 20% of post-TAVI patients experience heart failure or death within the first year.

Showing 1 to 4 of 4 results